Product Information
BMS-1001 is a monoclonal antibody that targets the death protein (DR5). DR5 is an oncogenic receptor that binds to the tumor necrosis factor receptor 1 (TNFR1) and activates NF-κB signaling. The activation of TNFR1 induces the production of proinflammatory cytokines, which contribute to the development of cancer. BMS-1001 has been shown to inhibit tumor growth in animal models by inhibiting TNFR1 signaling, without inducing any adverse effects. It has also been shown to induce tumor regression in patients with metastatic melanoma, prostate cancer, and lung cancer. In addition, BMS-1001 has been shown to be active against other types of cancers such as pancreatic cancer, colorectal cancer, and glioblastoma
Chemical properties
Technical inquiry about: 3D-NJD65003 BMS-1001
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
